Monoclonal Antibody Therapeutics
•74 stocks
•
Total Market Cap: Loading...
Market Cap Distribution
Price Performance Heatmap
5Y Price (Market Cap Weighted)
All Stocks (74)
%
| Company | Market Cap | Price |
|---|---|---|
|
Skyrizi and Rinvoq are monoclonal antibody therapeutics, directly manufactured and sold by AbbVie in immunology.
|
$431.71B |
$236.56
-1.80%
|
|
The company’s portfolio includes multiple monoclonal antibody therapeutics (e.g., Imfinzi, Imjudo, Ultomiris) across oncology and rare diseases.
|
$262.04B |
$84.53
-1.28%
|
|
Keytruda is a monoclonal antibody cancer therapy and a core revenue driver in Merck's oncology franchise.
|
$200.78B |
$79.96
-0.16%
|
|
Amgen's portfolio comprises monoclonal antibody therapeutics across multiple indications (including oncology and immunology).
|
$156.00B |
$290.13
-2.04%
|
|
Gilead leverages monoclonal antibody therapeutics in oncology (and ADCs rely on antibody components).
|
$145.76B |
$117.18
-0.40%
|
|
Dupixent and Beyfortus are monoclonal antibody therapeutics, a core Sanofi product class.
|
$120.19B |
$98.46
|
|
GSK develops Monoclonal Antibody Therapeutics (e.g., Nucala and other mAbs) as core medicines.
|
$88.43B |
$21.73
|
|
Zoetis markets monoclonal antibody therapeutics (e.g., OA pain mAbs like Librela/Solensia, Cytopoint).
|
$62.82B |
$141.11
-1.59%
|
|
Regeneron’s Dupixent and Libtayo represent core monoclonal antibody therapeutics driving a large portion of revenue.
|
$60.96B |
$564.63
-0.82%
|
|
TEVIMBRA is a monoclonal antibody (PD-1) therapy, representing a monoclonal antibody therapeutic program.
|
$34.59B |
$320.10
-3.00%
|
|
Ajovy is a monoclonal antibody therapeutic; Teva’s innovative portfolio includes antibody-based therapies.
|
$22.95B |
$20.01
+0.05%
|
|
LEQEMBI is a monoclonal antibody therapy; Biogen's pipeline also includes other monoclonal antibodies (felzartamab, litifilimab).
|
$21.48B |
$146.57
-2.29%
|
|
Genmab develops and commercializes monoclonal antibody therapeutics (e.g., EPKINLY, Tivdak) and relies on mAb-based modalities.
|
$21.05B |
$31.81
-0.28%
|
|
Unituxin (dinutuximab) is a monoclonal antibody cancer therapy, fitting Monoclonal Antibody Therapeutics.
|
$19.85B |
$440.00
-1.27%
|
|
Ivonescimab is an antibody-based therapeutic, aligning with the Monoclonal Antibody Therapeutics category.
|
$15.86B |
$21.35
-6.28%
|
|
abatacept is a monoclonal antibody; the pipeline includes mAb therapeutics in biosimilars.
|
$11.96B |
$14.34
+1.63%
|
|
CPMA and other monoclonal antibody platforms are highlighted as a major technology.
|
$9.74B |
$19.61
+3.59%
|
|
BRIUMVI is a monoclonal antibody therapeutic (anti-CD20) approved for relapsing MS, representing TG Therapeutics' flagship product.
|
$5.36B |
$33.76
-3.16%
|
|
Monoclonal Antibody Therapeutics as part of its targeting component for payload delivery.
|
$5.18B |
$42.95
+3.74%
|
|
VYVGART and other antibody-based therapeutics place monoclonal antibody therapeutics at the core of the business.
|
$3.43B |
$31.62
+0.86%
|
|
LockBody constructs are antibody-based therapeutics, aligning with monoclonal antibody modalities.
|
$2.98B |
$22.31
-2.75%
|
|
Hadlima and Emgality are monoclonal antibody therapeutics, aligning with Monoclonal Antibody Therapeutics.
|
$2.75B |
$10.65
+0.80%
|
|
IMVT-1402 is a monoclonal antibody therapeutic targeting FcRn, central to Immunovant's drug platform.
|
$2.75B |
$16.07
-0.77%
|
|
BEAM-103 is an anti-CD117 monoclonal antibody; Beam engages in monoclonal antibody therapeutics development as part of its programmatic strategy.
|
$2.65B |
$26.32
-7.58%
|
|
Celldex's lead product barzolvolimab is a humanized monoclonal antibody targeting KIT, a core monoclonal antibody therapeutic.
|
$1.74B |
$26.14
+1.79%
|
|
Viridian's lead assets are monoclonal antibodies (veligrotug and VRDN-003), placing the company in Monoclonal Antibody Therapeutics.
|
$1.71B |
$20.99
-3.94%
|
|
Domvanalimab is a monoclonal antibody therapeutic for cancer, placing Arcus in monoclonal antibody therapeutics.
|
$1.55B |
$14.60
-4.20%
|
|
Niktimvo (axatilimab-csfr) is a monoclonal antibody therapeutic, aligning with 'Monoclonal Antibody Therapeutics'.
|
$1.38B |
$16.06
-1.35%
|
|
NKTR-0165 is a monoclonal antibody therapeutic; direct product class is monoclonal antibodies.
|
$1.08B |
$58.85
+2.65%
|
|
Verekitug is a monoclonal antibody therapeutic candidate, corresponding to Monoclonal Antibody Therapeutics.
|
$1.06B |
$19.62
-0.91%
|
|
Zenas BioPharma's lead asset obexelimab is a monoclonal antibody therapeutic
|
$963.44M |
$23.03
+5.84%
|
|
Rosnilimab and ANB033/ANB101 are monoclonal antibody therapeutics in AnaptysBio's wholly-owned immunology pipeline.
|
$921.67M |
$31.37
-2.15%
|
|
OCS-02 uses licaminlimab, an antibody-based therapeutic, placing the company in the monoclonal antibody therapeutics space.
|
$884.62M |
$21.09
-1.91%
|
|
UGN-301 is an anti-CTLA-4 monoclonal antibody pipeline candidate, aligning with Monoclonal Antibody Therapeutics.
|
$802.27M |
$17.40
+0.87%
|
|
TBEVibart is an Fc-engineered monoclonal antibody component in the HDV/HBV program.
|
$758.93M |
$5.49
+5.98%
|
|
Ersodetug is a monoclonal antibody therapeutic, aligning with Monoclonal Antibody Therapeutics.
|
$707.24M |
$8.27
-6.02%
|
|
Lead assets are monoclonal antibody therapeutics used to treat retinal diseases.
|
$626.30M |
$11.87
-11.42%
|
|
Monoclonal Antibody Therapeutics: mupadolimab (anti-CD73) is a monoclonal antibody in Corvus's historical licensing context.
|
$569.88M |
$7.39
+11.30%
|
|
SLK is an antibody-based therapeutic, aligning with Monoclonal Antibody Therapeutics.
|
$541.24M |
$8.43
+11.95%
|
|
Core business involves monoclonal antibody therapeutics targeting neurodegenerative diseases (e.g., PRX012) and related pipeline assets.
|
$540.96M |
$10.05
-2.80%
|
|
Monoclonal antibody therapeutics targeting uPAR (MNPR-101).
|
$537.04M |
$87.82
-14.34%
|
|
Develops monoclonal antibody therapeutics (e.g., INBRX-109, INBRX-106) for cancer.
|
$516.07M |
$35.38
-0.76%
|
|
RPT904 is a monoclonal antibody targeting IgE, classifying as Monoclonal Antibody Therapeutics.
|
$443.00M |
$26.79
-10.52%
|
|
ZYNLONTA utilizes a monoclonal antibody component, aligning ADCT with Monoclonal Antibody Therapeutics.
|
$404.65M |
$4.36
+6.86%
|
|
Lead program iluzanebart is a monoclonal antibody therapeutic targeting TREM2.
|
$375.71M |
$8.05
|
|
AC Immune develops monoclonal antibodies via SupraAntigen; its pipeline includes antibody-based immunotherapies, fitting Monoclonal Antibody Therapeutics.
|
$354.43M |
$3.55
+0.28%
|
|
ANX005 (tanruprubart) is a monoclonal antibody therapeutic targeting C1q.
|
$340.11M |
$3.10
-4.91%
|
|
IMP761 is a monoclonal antibody therapeutic, aligning with Monoclonal Antibody Therapeutics.
|
$292.57M |
$2.01
-2.90%
|
|
PROBODY antibodies and ADCs align with Monoclonal Antibody Therapeutics as a core modality.
|
$266.05M |
$3.30
+1.23%
|
|
Narsoplimab and OMS1029/zaltenibart are monoclonal antibody therapeutics.
|
$245.50M |
$4.19
-8.71%
|
|
Therapies leverage monoclonal antibody components as part of the ADC modality.
|
$229.21M |
$3.70
-3.39%
|
|
Lonigutamab is a monoclonal antibody therapeutic developed by ACELYRIN for Thyroid Eye Disease.
|
$228.61M |
$2.27
|
|
Lead product Foralumab is a fully human monoclonal antibody, making Monoclonal Antibody Therapeutics a core directly produced asset.
|
$210.30M |
$2.04
-5.56%
|
|
Company directly develops and commercializes monoclonal antibody therapeutics, including PEMGARDA, and a pipeline candidate (VYD2311).
|
$195.54M |
$1.63
+9.40%
|
|
LOQTORZI is a monoclonal antibody PD-1 inhibitor and the lead product, representing direct monoclonal antibody therapeutics.
|
$193.61M |
$1.67
-9.73%
|
|
Nimacimab is a monoclonal antibody therapeutic targeting CB1 for obesity, representing Skye's core product.
|
$127.35M |
$3.96
-3.77%
|
|
SL-325 is a high-affinity monoclonal antibody targeting DR3, representing the core antibody therapeutic lead.
|
$109.21M |
$2.28
+1.33%
|
|
Develops monoclonal antibody therapeutics (including engineered bispecifics and antibodies), a central product category.
|
$106.62M |
$1.69
-4.52%
|
|
Lead asset sabirnetug is a monoclonal antibody therapeutic targeting soluble AßOs in Alzheimer's disease; qualifies as Monoclonal Antibody Therapeutics.
|
$104.79M |
$1.73
-3.35%
|
|
Evorpacept is a monoclonal antibody targeting CD47, aligning with Monoclonal Antibody Therapeutics.
|
$99.94M |
$1.76
-5.88%
|
|
Lead asset CBP-201 is a monoclonal antibody targeting IL-4Rα, placing CNTB's direct product category in Monoclonal Antibody Therapeutics.
|
$98.90M |
$1.74
-17.77%
|
|
DMAbs are DNA-encoded monoclonal antibodies, tying INOVIO to monoclonal antibody therapeutics.
|
$94.25M |
$2.57
-1.91%
|
|
Develops monoclonal antibody therapeutics (SAFEbody/POWERbody platforms) for cancer.
|
$86.33M |
$1.95
-1.52%
|
|
Vilobelimab is a monoclonal antibody targeting C5a, placing InflaRx in the Monoclonal Antibody Therapeutics category.
|
$81.26M |
$1.38
-4.83%
|
|
Bispecific antibodies are a form of monoclonal antibody therapeutics; CNTX develops antibody-based therapies.
|
$81.01M |
$0.89
-1.06%
|
|
Cosibelimab-based assets (UnLOXCYT) are monoclonal antibody therapeutics within Fortress's Checkpoint Therapeutics exposure.
|
$80.13M |
$2.71
-3.56%
|
|
ANL's antibody-based assets place it in the monoclonal antibody therapeutics landscape.
|
$57.88M |
$1.57
-7.10%
|
|
EQ001 (itolizumab) is a monoclonal antibody therapeutic, a core product category for EQ.
|
$47.51M |
$1.45
+9.02%
|
|
RADX has PSA-mAb and B7-H3 mAb assets, indicating monoclonal antibody therapeutics in its pipeline.
|
$46.41M |
$7.03
-5.64%
|
|
Xilio's vilastobart is a monoclonal antibody therapeutic, directly aligning with Monoclonal Antibody Therapeutics.
|
$43.64M |
$0.84
-5.31%
|
|
Lead and preclinical programs are monoclonal antibodies (DKN-01 and FL-501), fitting Monoclonal Antibody Therapeutics.
|
$26.46M |
$0.64
-4.13%
|
|
RT-111 program demonstrates oral delivery of monoclonal antibodies (ustekinumab), representing a monoclonal antibody therapeutics focus via the platform.
|
$26.37M |
$0.46
-3.54%
|
|
Core modality includes monoclonal antibody therapeutics (e.g., TH023).
|
$7.93M |
$2.98
-7.45%
|
|
IC 100 is a humanized monoclonal IgG4 antibody targeting ASC, representing a direct Monoclonal Antibody Therapeutics product.
|
$350558 |
$0.14
-2.50%
|
Loading industry metrics...
Loading comparison data...
